Andrii Buvailo is a pharmaceutical industry analyst and writer, focusing on emerging companies (startups),
technologies and trends in drug discovery, as well as R&D outsourcing. His articles were published on Forbes.com,
and market research reports were referenced by some of the leading life science organizations.
Andrii is a Director of Ecommerce at Enamine Ltd -- a global supplier of fine chemicals and contract research
services for the pharmaceutical industry. In this role he is involved in IT-management (ecommerce applications and systems),
sales management and marketing activities, related to supporting drug discovery organizations across the globe with innovative
chemicals and research services. Apart from his role at Enamine, he oversees BiopharmaTrend.com, and industry analytics consultancy.
He received a master's degree in Inorganic Chemistry and a PhD in Physical Chemistry from Kyiv National Taras Shevchenko University.
He spent a year at Prof. Eric Borguet Group
at Temple University Department of Chemistry developing gas sensor and biosensor systems,
He also participated in numerous scientific projects in Ukraine, Belgium, and Germany (DAAD, Horizon 2020, NATO, CRDF grants), and
published in
high-impact research journals. Andrii has hands-on experience in structural and coordination chemistry, surface science, physical chemistry,
nanomaterials and gas sensors, as well as bioinorganic chemistry. He received extensive theoretical training in molecular biology,
medicinal chemistry, and computer-aided drug discovery.
(Last updated: July 2023) Pharmaceutical companies are increasingly outsourcing research activities to academic institutions, tech-driven companies, and private contract research …
The advent of artificial intelligence (AI) in healthcare has catalyzed an epoch of change, reshaping diagnostic procedures, therapeutic strategies, and …
We use cookies to personalise content and to analyse our traffic.
You consent to our cookies if you continue to use our website. Read more details in our
cookies policy.